Ray Dalio Novo Cure LTD Transaction History
Bridgewater Associates, LP
- $21.1 Billion
- Q4 2024
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Novo Cure LTD stock. As of the latest transaction made, Bridgewater Associates, LP holds 11,119 shares of NVCR stock, worth $241,393. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,119
Previous 39,383
71.77%
Holding current value
$241,393
Previous $615,000
46.18%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding NVCR
# of Institutions
284Shares Held
75.5MCall Options Held
1.28MPut Options Held
350K-
Black Rock Inc. New York, NY12.1MShares$263 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$256 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA8.87MShares$193 Million0.05% of portfolio
-
Capital World Investors Los Angeles, CA4.82MShares$105 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.81MShares$60.9 Million0.03% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $2.28B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...